| Emily Clare Ridge, OD | |
|
2350 Mount Pleasant Rd, Hernando, MS 38632-1909 | |
| (662) 429-4448 | |
| (662) 429-5975 |
| Full Name | Emily Clare Ridge |
|---|---|
| Gender | Female |
| Speciality | Optometry |
| Experience | 7 Years |
| Location | 2350 Mount Pleasant Rd, Hernando, Mississippi |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1861916991 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | 954 (Mississippi) | Primary |
| Provider Name | Desoto Eyecare Inc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1376576884 PECOS PAC ID: 1254232655 Enrollment ID: O20080721000259 |
News Archive
Light Sciences Oncology, Inc. (LSO) today announced the treatment of the first patients in a Phase 2 clinical trial of its innovative targeted drug treatment Aptocine(TM) (talaporfin sodium) in Benign Prostatic Hyperplasia (BPH). The Phase 2 trial expands the Aptocine BPH development program on the basis of a Phase 1 study at escalating light doses. In the open-label Phase 2 trial, Aptocine is being tested for safety and efficacy in 40 patients with lower urinary tract symptoms (LUTS) due to BPH. Aptocine is also in two Phase 3 clinical trials for solid tumors in the liver as well as preclinical development for prostate cancer.
Living in an area with more fast food outlets and convenience stores than supermarkets and grocers has been associated with obesity in a Canadian study. Researchers writing in the open access journal BMC Public Health have shown that your local food environment can affect your weight.
Washington Post columnist Stephen Barr on Monday examined the Peace Corps' policy regarding HIV-positive volunteers. According to Barr, Jeremiah Johnson, a former volunteer in Ukraine, recently was discharged by the agency after he was diagnosed as HIV-positive.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
› Verified 5 days ago
| Provider Name | Elite Eyecare |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1508502774 PECOS PAC ID: 6406233030 Enrollment ID: O20220519001448 |
News Archive
Light Sciences Oncology, Inc. (LSO) today announced the treatment of the first patients in a Phase 2 clinical trial of its innovative targeted drug treatment Aptocine(TM) (talaporfin sodium) in Benign Prostatic Hyperplasia (BPH). The Phase 2 trial expands the Aptocine BPH development program on the basis of a Phase 1 study at escalating light doses. In the open-label Phase 2 trial, Aptocine is being tested for safety and efficacy in 40 patients with lower urinary tract symptoms (LUTS) due to BPH. Aptocine is also in two Phase 3 clinical trials for solid tumors in the liver as well as preclinical development for prostate cancer.
Living in an area with more fast food outlets and convenience stores than supermarkets and grocers has been associated with obesity in a Canadian study. Researchers writing in the open access journal BMC Public Health have shown that your local food environment can affect your weight.
Washington Post columnist Stephen Barr on Monday examined the Peace Corps' policy regarding HIV-positive volunteers. According to Barr, Jeremiah Johnson, a former volunteer in Ukraine, recently was discharged by the agency after he was diagnosed as HIV-positive.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Emily Clare Ridge, OD 2350 Mount Pleasant Rd, Hernando, MS 38632-1909 Ph: (662) 429-4448 | Emily Clare Ridge, OD 2350 Mount Pleasant Rd, Hernando, MS 38632-1909 Ph: (662) 429-4448 |
News Archive
Light Sciences Oncology, Inc. (LSO) today announced the treatment of the first patients in a Phase 2 clinical trial of its innovative targeted drug treatment Aptocine(TM) (talaporfin sodium) in Benign Prostatic Hyperplasia (BPH). The Phase 2 trial expands the Aptocine BPH development program on the basis of a Phase 1 study at escalating light doses. In the open-label Phase 2 trial, Aptocine is being tested for safety and efficacy in 40 patients with lower urinary tract symptoms (LUTS) due to BPH. Aptocine is also in two Phase 3 clinical trials for solid tumors in the liver as well as preclinical development for prostate cancer.
Living in an area with more fast food outlets and convenience stores than supermarkets and grocers has been associated with obesity in a Canadian study. Researchers writing in the open access journal BMC Public Health have shown that your local food environment can affect your weight.
Washington Post columnist Stephen Barr on Monday examined the Peace Corps' policy regarding HIV-positive volunteers. According to Barr, Jeremiah Johnson, a former volunteer in Ukraine, recently was discharged by the agency after he was diagnosed as HIV-positive.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
› Verified 5 days ago
Vrf Eye Specialty Group, Plc Optometrist Medicare: Not Enrolled in Medicare Practice Location: 2350 Mount Pleasant Rd, Hernando, MS 38632 Phone: 662-429-4448 | |
Shackelford Family Eyecare Optometrist Medicare: Not Enrolled in Medicare Practice Location: 2350 Mount Pleasant Rd, Hernando, MS 38632 Phone: 662-429-4448 Fax: 662-429-5975 | |
Henderson Vision Center Optometrist Medicare: Not Enrolled in Medicare Practice Location: 2600 Mcingvale Rd, Hernando, MS 38632 Phone: 662-429-7099 Fax: 662-469-4091 | |
Dr. John D Carlson, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 2170 Highway 51 S Ste 6, Hernando, MS 38632 Phone: 662-449-1384 Fax: 662-449-1385 | |
Elite Eyecare Optometrist Medicare: Medicare Enrolled Practice Location: 2631 Mcingvale Rd Ste 104, Hernando, MS 38632 Phone: 662-934-2408 | |
Raymond Calvin Shackelford, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 2350 Mt Pleasant Rd, Hernando, MS 38632 Phone: 662-429-4448 Fax: 662-429-5975 | |
Dr. Michael D Honeycutt, OD Optometrist Medicare: Medicare Enrolled Practice Location: 165 W South St, Hernando, MS 38632 Phone: 662-429-4328 Fax: 662-429-4328 |